Re: Assessing CD52 status during Campath - 1H therapy

From: Frederic Preffer (preffer@helix.mgh.harvard.edu)
Date: Fri Nov 09 2001 - 17:10:45 EST


Roger

If i get your problem correctly, why not test to see if the T cells are
coated with anti-human [=drug] antibody and just not responding?... that
would at least answer some of the questions you have.
use something like a goat anti-human that you know stains the drug. Make
sure to add a CD19 to detect and distinguish normally 'coated' B cells.

F Preffer



At 06:54 PM 11/6/01 -0500, Roger D. Klein, M.D. wrote:
>
>I would like to repeat flow cytometry on the blood of
>a patient with HTLV-1 T-Cell Leukemia/Lymphoma (CD 4+,
>CD 25+), to assess CD52 status.  The patient is currently
>being treated with Campath - 1H, a humanized monoclonal
>antibody that is reactive with CD52 (his disease was
>found to be CD52+ in the past).  The patient no longer
>seems to be responding to Campath therapy,and his
>disease now appears to be CD 52- by flow.  I am concerned
>that the Campath - 1 H (most recent dose yesterday) could
>be masking any CD52 present on the patient's malignant cells.
>Does anybody know of literature addressing this issue, or
>otherwise have suggestions.  Thank you very much for any
>assistance that you can provide.
>
>Roger Klein, M.D.
>
Frederic I. Preffer
Department of Pathology
Charlestown Navy Yard- 7140
149 13th Street
Massachusetts General Hospital -East
Charlestown, MA 02129

voice     [617] 726-7481
fax        [617] 724-3164



This archive was generated by hypermail 2b29 : Sun Jan 05 2003 - 19:01:38 EST